| Newton Study (NEW Dosing MainTenance Therapy Ovarian CaNcer) (NCT03891576) | Mario Negri Institute for Pharmacological Research | 2019-11-13 |
| Study BT5528-100 in Patients With Advanced Solid Tumors Associated With EphA2 Expression (NCT04180371) | BicycleTx Limited | 2019-11-07 |
| Real World Data Analysis of PARP Inhibitors Use in Patients With Ovarian Cancer (NCT04724031) | Hellenic Cooperative Oncology Group | 2019-11-01 |
| Study of IMP4297 in Patients With BRCA1/2 Mutation Ovarian Cancer (NCT04089189) | Impact Therapeutics, Inc. | 2019-10-28 |
| The Role of Cytomegalovirus and Inflammation on Patient Symptoms and Outcomes in Ovarian Cancer (NCT03921658) | University of Minnesota | 2019-10-22 |
| Tolerance of Intraperitoneal (IP) Nivolumab After Extensive Debulking Surgery and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Patients With Advanced Ovarian Carcinoma (NCT03959761) | Hospices Civils de Lyon | 2019-10-17 |
| Study of NGM120 in Subjects With Advanced Solid Tumors, Pancreatic Cancer, and Prostate Cancer Using Combination Therapy (NCT04068896) | NGM Biopharmaceuticals, Inc | 2019-10-16 |
| Optimal Timing of BR55 CEUS of the Ovaries (NCT04248153) | Bracco Diagnostics, Inc | 2019-10-14 |
| Characterization of Biophysical Stromal Properties in Human Cancer: Towards Personalized Computational Oncology (NCT04512209) | University Hospital, Ghent | 2019-10-11 |
| Naptumomab Estafenatox in Combination With Durvalumab in Subjects With Selected Advanced or Metastatic Solid Tumor, Including a Cohort Expansion in Esophageal Cancer. (NCT03983954) | NeoTX Therapeutics Ltd. | 2019-10-10 |
| A Study of CART-TnMUC1 in Patients With TnMUC1-Positive Advanced Cancers (NCT04025216) | Kite, A Gilead Company | 2019-10-10 |
| A Phase 1/2 Study of CYT-0851 in B-Cell Malignancies and Advanced Solid Tumors (NCT03997968) | Cyteir Therapeutics, Inc. | 2019-10-09 |
| Acupressure for Fatigue in Ovarian Cancer Survivors (NCT03763838) | University of Michigan Rogel Cancer Center | 2019-10-07 |
| Galinpepimut-S in Combination With Pembrolizumab in Patients With Selected Advanced Cancers (NCT03761914) | Sellas Life Sciences Group | 2019-09-30 |
| Study to Evaluate the Safety of Nanoxel M Inj. (NCT04066335) | Samyang Biopharmaceuticals Corporation | 2019-09-18 |
| Detection of Circulating Tumor DNA Through Liquid Biopsies in Ovarian Cancer Patients and Evaluation of Prognostic and Predictive Values of Circulating Tumor DNA Assay. (NCT05504174) | Yonsei University | 2019-09-10 |
| Efficacy of Platinum-based Chemotherapy in Platinum-resistant Ovarian Cancer) (EPITOC) (NCT04055038) | Blokhin's Russian Cancer Research Center | 2019-09-01 |
| Apatinib With Albumin-bound Paclitaxel in Patients With Platinum-resistant Recurrent Ovarian Cancer (NCT03942068) | Henan Cancer Hospital | 2019-09-01 |
| ADP-A2M4CD8 as Monotherapy or in Combination With Either Nivolumab or Pembrolizumab in HLA-A2+ Subjects With MAGE-A4 Positive Tumors (SURPASS) (NCT04044859) | USWM CT, LLC | 2019-08-20 |
| Apatinib and Etoposide Capsule Versus Weekly Paclitaxel in Patients With Platinum Resistant Ovarian Cancer (NCT04000295) | Jiangsu HengRui Medicine Co., Ltd. | 2019-08-16 |
| The Fourth Generation CART-cell Therapy for Refractory-Relapsed Ovarian Cancer (NCT03814447) | Shanghai 6th People's Hospital | 2019-08-16 |
| A Study to Evaluate ONM-100, an Intraoperative Fluorescence Imaging Agent for the Detection of Cancer (NCT03735680) | OncoNano Medicine, Inc. | 2019-08-09 |
| ICG-Enabled Mapping of Ovarian Sentinel Lymph Nodes: A Feasibility Study (NCT04051502) | Memorial Sloan Kettering Cancer Center | 2019-08-05 |
| Pamiparib in Fusion Positive, Reversion Negative High Grade Serous Ovarian Cancer or Carcinosarcoma With BRCA1/2 Gene Mutations If Progression on Substrate Poly ADP Ribose Polymerase Inhibitbor (PARPI) or Chemotherapy (NCT03933761) | Australia New Zealand Gynaecological Oncology Group | 2019-07-29 |
| PARP Inhibition During Pre-surgical Window in Breast/Ovary Cancer (NCT04041128) | University of Texas Southwestern Medical Center | 2019-07-23 |
| The DETECT Study: Discovery and Evaluation of Testing for Endometrial and Ovarian Cancer in Tampons (NCT03538665) | University of Alabama at Birmingham | 2019-07-01 |
| Chiauranib in Combination With Chemotherapy in Patients With Ovarian Cancer (NCT03901118) | Chipscreen Biosciences, Ltd. | 2019-07-01 |
| A Study to Evaluate Rucaparib in Combination With Other Anticancer Agents in Participants With a Solid Tumor (SEASTAR) (NCT03992131) | pharmaand GmbH | 2019-06-28 |
| Study of Nanrilkefusp Alfa Alone and With Pembrolizumab in Adult Patients With Advanced/Metastatic Solid Tumors (NCT04234113) | SOTIO Biotech AG | 2019-06-13 |
| A Study Evaluating the Safety, Pharmacokinetics and Efficacy of Ipatasertib Administered in Combination With Rucaparib in Participants With Advanced Breast, Ovarian Cancer, and Prostate Cancer. (NCT03840200) | Hoffmann-La Roche | 2019-06-12 |
| Efficacy of Paxman Scalp Cooling to Prevent Chemo Induced Alopecia in Black Patients With Breast or GYN Cancers (NCT04626895) | Medstar Health Research Institute | 2019-06-04 |
| APG-2449 in Patients With Advanced Solid Tumors (NCT03917043) | Ascentage Pharma Group Inc. | 2019-05-27 |
| Exploring the Potential of Novel Biomarkers Based on Plasma microRNAs for a Better Management of Pelvic Gynecologic Tumors (NCT03776630) | Assistance Publique - Hôpitaux de Paris | 2019-05-23 |
| Pilot Study of Liposomal Bupivacaine Redosing in Patients Undergoing Major Gynecologic Procedures (NCT04849858) | University of California, Irvine | 2019-05-20 |
| Trial of Pembrolizumab Following Weekly Paclitaxel for Platinum-resistant Ovarian, Fallopian Tube or Peritoneal Cancer (NCT03430700) | University College, London | 2019-05-16 |
| Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Ovarian Cancer (CHIPPI) (NCT03842982) | Centre Oscar Lambret | 2019-05-03 |
| A Trial of Maintenance Treatment With Fluzoparib Versus Placebo in Relapsed Ovarian Cancer Patients (NCT03863860) | Jiangsu HengRui Medicine Co., Ltd. | 2019-04-30 |
| A Study of TRK-950 in Combinations With Anti-Cancer Treatment Regimens in Patients With Advanced Solid Tumors (NCT03872947) | Toray Industries, Inc | 2019-04-26 |
| Anlotinib for Patients With Platinum Resistant or Refractory Ovarian Cancer (NCT03924882) | Second Affiliated Hospital, Zhejiang University, School of Medicine | 2019-04-25 |
| MESO-CAR T Cells Therapy for Relapsed and Refractory Epithelial Ovarian Cancer (NCT03916679) | Second Affiliated Hospital, Zhejiang University, School of Medicine | 2019-04-20 |
| Clinical Validation of the InterVenn Ovarian CAncer Liquid Biopsy (NCT03837327) | Venn Biosciences Corporation | 2019-04-16 |
| Phase 1/2 Trial of Gavo-cel (TC-210) in Patients With Advanced Mesothelin-Expressing Cancer (NCT03907852) | TCR2 Therapeutics | 2019-04-15 |
| Clinical Pre-screening Protocol for Ovarian Cancer (NCT03877796) | Allarity Therapeutics | 2019-04-11 |
| MRx0518 in Patients With Solid Tumours Waiting Surgical Removal of the Tumour (NCT03934827) | Imperial College London | 2019-04-10 |
| MESO-CAR T Cells Therapy for Relapsed and Refractory Ovarian Cancer (NCT03799913) | Zhejiang University | 2019-04-10 |
| NIraparib and Quality of LifE is a Longitudinal Study Evaluating in Real Life the Tolerability of Niraparib. (NCT03752216) | ARCAGY/ GINECO GROUP | 2019-04-03 |
| Safety and Efficacy of the Fully Humanized Anti - VEGF Monoclonal Antibody LYN00101 (NCT03644459) | Lynkcell Inc. | 2019-04-03 |
| The IGF Axis Involvement in Immune Tumor Microenvironment in Ovarian Cancer and Its Clinical Significance (NCT03846856) | Hillel Yaffe Medical Center | 2019-04-01 |
| Effect of Tumor Treating Fields (TTFields, 200 kHz) Concomitant With Weekly Paclitaxel for the Treatment of Recurrent Ovarian Cancer (ENGOT-ov50 / GOG-3029 / INNOVATE-3) (NCT03940196) | NovoCure Ltd. | 2019-03-22 |
| Fc-Engineered Anti-CTLA-4 Monoclonal Antibody in Advanced Cancer (NCT03860272) | Agenus Inc. | 2019-03-20 |
| A Study of Weekly Tisotumab Vedotin for Patients With Platinum-Resistant Ovarian Cancer With Safety Run-in (innovaTV 208) (NCT03657043) | Seagen Inc. | 2019-03-20 |
| HIPEC After Initial CRS in Patients Who Have Received NACT (NCT03540017) | Northwell Health | 2019-03-12 |
| Constitution of ex Vivo Ovarian Tumor Models for the Validation of the Interest of Innovative Therapies and the Search for Tumor or Circulating Biomarkers Predictive of Treatment Response (NCT03831230) | Centre Francois Baclesse | 2019-03-07 |
| Phase Ib/II Study of Carboplatin + M6620 + Avelumab in PARPi-resistant Ovarian Cancer (NCT03704467) | EMD Serono Research & Development Institute, Inc. | 2019-03-04 |
| Efficacy and Safety of Paclitaxel for Injection (Albumin-bound) for First-line Chemotherapy of Ovarian Cancer (NCT03818282) | Huazhong University of Science and Technology | 2019-03-01 |
| Efficacy and Safety of Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) in Previously Treated Participants With Select Solid Tumors (MK-7902-005/E7080-G000-224/LEAP-005) (NCT03797326) | Merck Sharp & Dohme LLC | 2019-02-12 |
| Opioid Free Anaesthesia in Oncologic Gynaecological Surgery: Is There Any Benefit? (NCT05448586) | Instituto de Investigación Hospital Universitario La Paz | 2019-02-02 |
| Study of STRO-002, an Anti-Folate Receptor Alpha (FolRα) Antibody Drug Conjugate in Ovarian & Endometrial Cancers (NCT03748186) | Sutro Biopharma, Inc. | 2019-02-01 |
| A Phase 1 Study of [225Ac]-FPI-1434 Injection (NCT03746431) | Fusion Pharmaceuticals Inc. | 2019-01-17 |
| A Study of Niraparib in Combination With Brivanib in Recurrent Ovarian Cancer (NCT03895788) | Hunan Cancer Hospital | 2019-01-14 |
| A Trial to Evaluate Safety, Tolerability, and Preliminary Efficacy of Misetionamide (GP-2250) as Monotherapy or in Combination With Gemcitabine (NCT03854110) | Persevere Therapeutics Inc. | 2019-01-14 |
| A Clinical Study of Cobimetinib Administered in Combination With Niraparib, With or Without Atezolizumab to Patients With Advanced Platinum-sensitive Ovarian Cancer (NCT03695380) | Hoffmann-La Roche | 2019-01-09 |
| 18F-ASIS PET/CT Imaging of Tissue Factor Expression In Patients With Primary and Metastastic Cancer (NCT03790423) | Rigshospitalet, Denmark | 2019-01-03 |
| MOLecular Characterization and Treatment of THYroid Carcinoma on Struma Ovarii (NCT04053114) | Institut Bergonié | 2019-01-01 |
| STOP OVarian CAncer; Implementation of the Opportunistic Salpingectomy in the Netherlands (NCT04470921) | Radboud University Medical Center | 2019-01-01 |
| Japan Phase 2 Study of Niraparib (Maintenance Therapy) in Participants With Relapsed Ovarian Cancer (NCT03759587) | Takeda | 2018-12-28 |
| Japan Phase 2 Study of Niraparib in Participants With Advanced, Relapsed Ovarian Cancer (NCT03759600) | Takeda | 2018-12-26 |
| Study of an Immunotherapeutic, DPX-Survivac, in Combination With Low Dose Cyclophosphamide & Pembrolizumab, in Subjects With Selected Advanced & Recurrent Solid Tumors (NCT03836352) | ImmunoVaccine Technologies, Inc. (IMV Inc.) | 2018-12-21 |
| Study of Chemotherapy With Pembrolizumab (MK-3475) Followed by Maintenance With Olaparib (MK-7339) for the First-Line Treatment of Women With BRCA Non-mutated Advanced Epithelial Ovarian Cancer (EOC) (MK-7339-001/KEYLYNK-001/ENGOT-ov43/GOG-3036) (NCT03740165) | Merck Sharp & Dohme LLC | 2018-12-18 |
| Arginase-1 Peptide Vaccine in Patients With Metastatic Solid Tumors (NCT03689192) | Herlev Hospital | 2018-12-17 |
| Continued Access to RXDX-105 (NCT03784378) | Memorial Sloan Kettering Cancer Center | 2018-12-14 |
| BR55 in Characterization of Ovarian Lesions (NCT03493464) | Bracco Diagnostics, Inc | 2018-12-13 |
| Efficacy and Safety Study of AVB-S6-500 in Patients With Platinum-Resistant Recurrent Ovarian Cancer (NCT03639246) | Aravive, Inc. | 2018-12-06 |
| Pembrolizumab in Combination with Bevacizumab and Pegylated Liposomal Doxorubicin in Patients with Ovarian Cancer (NCT03596281) | Gustave Roussy, Cancer Campus, Grand Paris | 2018-12-05 |
| The Effects of Exercise on Distress, Quality of Life, and Biomarkers in Ovarian Cancer Survivors (NCT03641287) | University of Washington | 2018-12-05 |
| Predictive Value of Progastrin Titer at Diagnosis and of Progastrin Kinetics During Treatment in Cancer Patients (NCT03787056) | Hospices Civils de Lyon | 2018-12-04 |
| European Trial on Enhanced DNA Repair Inhibition in Ovarian Cancer (NCT03783949) | Universitaire Ziekenhuizen KU Leuven | 2018-11-30 |
| Non-coding RNA in the Exosome of the Epithelia Ovarian Cancer (NCT03738319) | Lei Li | 2018-11-10 |
| Study of ADCT-301 in Patients With Selected Advanced Solid Tumors (NCT03621982) | ADC Therapeutics S.A. | 2018-11-09 |
| Trans-Artery/Intra-Tumor Infusion of Checkpoint Inhibitors Plus Chemodrug for Immunotherapy of Advanced Solid Tumors (NCT03755739) | Second Affiliated Hospital of Guangzhou Medical University | 2018-11-01 |
| Early Detection of High Grade Ovarian Cancer Using Uterine Lavage EHUD Study and Duplex Sequencing (NCT04823871) | Paul Speiser, Prof.MD, | 2018-11-01 |
| Clinical Study on Anti-tumor Effect Induced by Activated Primary Natural Killer（NK）Cells (NCT03634501) | Xuanwu Hospital, Beijing | 2018-10-26 |
| MOv19-BBz CAR T Cells in aFR Expressing Recurrent High Grade Serous Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (NCT03585764) | University of Pennsylvania | 2018-10-24 |
| A Study to Evaluate Safety/Tolerability of Immunotherapy Combinations in Participants With Triple-Negative Breast Cancer or Gynecologic Malignancies (NCT03719326) | Arcus Biosciences, Inc. | 2018-10-15 |
| Efficacy Study of CPC634 (CriPec® Docetaxel) in Platinum Resistant Ovarian Cancer (NCT03742713) | Cristal Therapeutics | 2018-10-01 |
| A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies (NCT03652077) | Incyte Corporation | 2018-09-24 |
| Dual mTorc Inhibition in advanCed/Recurrent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer (of Clear Cell, Endometrioid and High Grade Serous Type, and Carcinosarcoma) (NCT03648489) | Imperial College London | 2018-09-21 |
| Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer (NCT03412877) | National Cancer Institute (NCI) | 2018-09-06 |
| COM701 (an Inhibitor of PVRIG) in Subjects With Advanced Solid Tumors. (NCT03667716) | Compugen Ltd | 2018-09-06 |
| 4FMFES-PET Imaging of Endometrial and Ovarian Cancers (NCT04823065) | Centre de recherche du Centre hospitalier universitaire de Sherbrooke | 2018-09-01 |
| Compare Fallopian Tube Cells Collected by Cytuity With Removed Ovarian/Tubal Tissue to Determine Presence of Malignancy (NCT03593681) | Boston Scientific Corporation | 2018-08-27 |
| Blood Sample Collection to Evaluate Biomarkers in Subjects With Untreated Solid Tumors (NCT03662204) | Exact Sciences Corporation | 2018-08-23 |
| A Study of the Efficacy and Safety of Bevacizumab in Chinese Women With Newly Diagnosed, Previously Untreated Stage III or Stage IV Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (NCT03635489) | Hoffmann-La Roche | 2018-08-15 |
| Pilot Study of Rosuvastatin and Enoxaparin Thromboprophylaxis Following Ovarian Cancer Surgery (O-STAT Study) (NCT03532139) | Beth Israel Deaconess Medical Center | 2018-07-25 |
| A Study to Evaluate the Safety and Tolerability of Immunotherapy Combinations in Participants With Advanced Malignancies (NCT03629756) | Arcus Biosciences, Inc. | 2018-07-24 |
| Stepping Into Survivorship: Harnessing Behavioral Economics to Improve Quality of Life in Ovarian Cancer (NCT03364673) | Dana-Farber Cancer Institute | 2018-07-20 |
| Avelumab and Talazoparib in Untreated Advanced Ovarian Cancer (JAVELIN OVARIAN PARP 100) (NCT03642132) | Pfizer | 2018-07-19 |
| A Phase I/Ib Study of NZV930 Alone and in Combination With PDR001 and /or NIR178 in Patients With Advanced Malignancies. (NCT03549000) | Novartis Pharmaceuticals | 2018-07-18 |
| Clinical Study of Apatinib in the Treatment of Platinum Resistant Recurrent Ovarian Cancer (NCT03587129) | First Affiliated Hospital of Harbin Medical University | 2018-07-10 |
| BEACON - ABC in Recurrent Platinum Resistant HGSOC (NCT03363867) | Peter MacCallum Cancer Centre, Australia | 2018-07-10 |